0001213900-23-095420.txt : 20231213 0001213900-23-095420.hdr.sgml : 20231213 20231213164508 ACCESSION NUMBER: 0001213900-23-095420 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231211 FILED AS OF DATE: 20231213 DATE AS OF CHANGE: 20231213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wolfson Marina CENTRAL INDEX KEY: 0001797360 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38762 FILM NUMBER: 231484557 MAIL ADDRESS: STREET 1: C/O BIOMX LTD. STREET 2: 7 PINHAS SAPIR ST., FLOOR 2 CITY: NESS ZIONA STATE: L3 ZIP: 7414002 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BiomX Inc. CENTRAL INDEX KEY: 0001739174 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 22 EINSTEIN ST., 4TH FLOOR CITY: NESS ZIONA STATE: L3 ZIP: 7414003 BUSINESS PHONE: (972) 72 394 2377 MAIL ADDRESS: STREET 1: 22 EINSTEIN ST., 4TH FLOOR CITY: NESS ZIONA STATE: L3 ZIP: 7414003 FORMER COMPANY: FORMER CONFORMED NAME: Chardan Healthcare Acquisition Corp. DATE OF NAME CHANGE: 20180430 4 1 ownership.xml X0508 4 2023-12-11 0 0001739174 BiomX Inc. PHGE 0001797360 Wolfson Marina C/O BIOMX INC., 22 EINSTEIN ST., FLOOR 4 NESS ZIONA, L3 7414003 ISRAEL 0 1 0 0 Chief Financial Officer 0 Common Stock Options - Right to Buy 6.21 2023-12-11 4 D 0 36000 D 2030-03-25 Common Stock 36000 0 D Common Stock Options - Right to Buy 0.2749 2023-12-11 4 A 0 9474 A 2030-03-25 Common Stock 9474 9474 D Common Stock Options - Right to Buy 7.02 2023-12-11 4 D 0 33250 D 2031-03-30 Common Stock 33250 0 D Common Stock Options - Right to Buy 0.2749 2023-12-11 4 A 0 8750 A 2031-03-30 Common Stock 8750 8750 D Common Stock Options - Right to Buy 1.41 2023-12-11 4 D 0 50000 D 2032-03-29 Common Stock 50000 0 D Common Stock Options - Right to Buy 0.2749 2023-12-11 4 A 0 35715 A 2032-03-29 Common Stock 35715 35715 D On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 36,000 shares of the Issuer's common stock granted to the Reporting Person on March 25, 2020. In exchange, the Reporting Person received a replacement option, for 9,474 shares, having an exercise price of $0.2749 per share. The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 25, 2021, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024. On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 33,250 shares of the Issuer's common stock granted to the Reporting Person on March 30, 2021. In exchange, the Reporting Person received a replacement option, for 8,750 shares, having an exercise price of $0.2749 per share. The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 30, 2022, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024. On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 50,000 shares of the Issuer's common stock granted to the Reporting Person on March 29, 2022. In exchange, the Reporting Person received a replacement option, for 35,715 shares, having an exercise price of $0.2749 per share. The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 29, 2023, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024. /s/ Marina Wolfson 2023-12-13